Study of Factors to Increase the Usage Rate of Generic Drugs in Platelet Aggregation Inhibitors
Inquiry: The Journal of Health Care Organization, Provision, and Financing, 2023 To reduce pharmacy-related medical expenses, it is necessary to reduce drug costs. One way to achieve this is by increasing the usage rate of generic drugs.
Takaaki Suzuki BS +9 more
doaj +1 more source
A Thrombocytopenic Thrombotic Purpura in a Patient With a Metastatic HER2+ Breast Cancer: Description of a Case Report. [PDF]
Clin Case RepABSTRACT Paraneoplastic (p) TTP is a rare syndrome characterized by an immune‐induced, generalized microangiopathy associated with solid or hematological tumors. This case, reporting a patient with a metastatic HER2+ breast cancer and a pTTP, highlights the rarity of this entity, its difficult and challenging diagnosis, and the complexity of its ...
Longo R +9 more
europepmc +2 more sources
Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials [PDF]
, 2009 <p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with
Cucchiara, B. +8 more
core +1 more source
Ticlopidine-induced cholestatic hepatitis: A case report and review of the literature
Italian Journal of Medicine, 2012 Introduction Cholestatic hepatitis is frequently a drug-related syndrome. We describe the case of a 57-year-old man who developed cholestatic hepatitis two months after starting therapy with ticlopidine following a carotid endarterectomy.Materials and ...
Luigi Anastasio +7 more
doaj +1 more source
BMC Neurology, 2021 Background Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but their relative effectiveness and harms still need to be clarified.
Cinzia Del Giovane +4 more
doaj +1 more source
Anticoagulant versus antiplatelet therapy for acute ischemic stroke [PDF]
, 2008 Acute ischaemic stroke is a leading cause of death in Canada and should be a priority in health care. This paper defines acute ischaemic stroke and provides current statistics, economic costs, risk factors, treatments, and management options.
core +1 more source
Newer agents in antiplatelet therapy: a review. [PDF]
, 2012 Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core +3 more sources
PLoS ONE, 2019 Background and purposeThe ticlopidine/Ginkgo biloba ext. combination drug (Yuclid) is used as an antiplatelet agent for prevention of vascular events since its approval in 2008.
Han-Gil Jeong +3 more
doaj +1 more source
Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. [PDF]
, 2015 BACKGROUND: Worldwide, coronary heart disease accounts for 7 million deaths each year. In Sweden, acute coronary syndrome (ACS) is a leading cause of hospitalization and is responsible for 1 in 4 deaths.
A Kumar +19 more
core +3 more sources
Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
Current Controlled Trials in Cardiovascular Medicine, 2000 The cornerstone in clinical evidence of the relative efficacy of thienopyridines (clopidogrel, ticlopidine) versus aspirin in the secondary prevention of vascular disease is the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events trial ...
Algra Ale, van Gijn Jan
doaj +1 more source